|4Feb 18, 4:30 PM ET

DesRosier Thomas 4

4 · Seres Therapeutics, Inc. · Filed Feb 18, 2026

Research Summary

AI-generated summary of this filing

Updated

Seres (MCRB) Co‑CEO Thomas DesRosier Sells 78 Shares (RSU)

What Happened
Thomas DesRosier (Co‑Chief Executive Officer & Co‑President; also Chief Legal Officer & EVP) reported RSU activity and sales tied to tax withholding. The filing shows 244 shares were acquired via exercise/conversion (RSU settlement). The same filing reports an open‑market sale of 78 shares at $8.47 each for $661, plus two derivative disposals of 133 shares and 111 shares (reported at $0), which are related to tax withholding.

This is not a purchase (no bullish buy); the transactions appear routine and tax‑related rather than a discretionary sale for investment reasons.

Key Details

  • Transaction date(s): February 15, 2026; Form 4 filed February 18, 2026.
  • Prices/values reported: open‑market sale 78 shares @ $8.47 = $661; two derivative disposals 133 and 111 shares @ $0 (withholding); 244 shares acquired via RSU conversion (no price reported).
  • Shares owned after transaction: Not specified in the provided filing details.
  • Notable footnotes: RSUs represent contingent rights to one share each (F1); the open‑market sale was effected under a Rule 10b5‑1 plan adopted March 2, 2023 and described as solely to cover taxes (F2); RSU vesting schedule details provided (F3, F4).
  • Filing timeliness: Filing occurred three days after the reported transaction date; Form 4s are generally due within two business days, so this may be outside the typical filing window.

Context

  • The derivative entries reflect RSU settlement and likely share withholding to cover taxes (the two derivative disposals equal the 244 shares reported acquired). The separate 78‑share open‑market sale was executed under a prearranged 10b5‑1 plan and is described as tax‑related.
  • Tax‑related sell‑to‑cover transactions are routine and do not necessarily indicate changes in insider sentiment.

Insider Transaction Report

Form 4
Period: 2026-02-15
DesRosier Thomas
See Remarks
Transactions
  • Exercise/Conversion

    Common Stock

    [F1]
    2026-02-15+2447,867 total
  • Sale

    Common Stock

    [F2]
    2026-02-15$8.47/sh78$6617,789 total
  • Exercise/Conversion

    Restricted Stock Units

    [F1][F3]
    2026-02-15133531 total
    Common Stock (133 underlying)
  • Exercise/Conversion

    Restricted Stock Units

    [F1][F4]
    2026-02-15111890 total
    Common Stock (111 underlying)
Footnotes (4)
  • [F1]Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.
  • [F2]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted by the reporting person on March 2, 2023, solely with the intent to cover taxes in connection with the vesting of the restricted stock units.
  • [F3]The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date.
  • [F4]The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2025. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date.
Signature
/s/ Thomas J. DesRosier|2026-02-18

Documents

1 file
  • 4
    ownership.xmlPrimary

    4